News Agency
The Times

Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program

  • Written by PR Newswire
Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program
  • Synaffix to provide Hummingbird Bioscience access to proprietary ADC technologies
  • Synaffix to receive up to $150m in upfront and milestone payments plus royalties 

SAN FRANCISCO, HOUSTON and SINGAPORE, Jan. 4, 2023 /PRNewswire/ -- Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform...

Read more: Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody...

Selecting Steel Plate for Industrial and Fabrication Projects

Start with the job requirements A successful fabrication project starts with material that suits the work it must perform. Choosing steel plate involves more than selecting a thickness from a stock list. Designers and procurement teams need to consider the load... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion